Update on diabetes mellitus: Prevention, treatment, and association with oral diseases

Oral Diseases

Volumn 14, Issue 2, 2008, Pages 105-114

  Skamagas, M ^a   Breen, T L ^a   LeRoith, D ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Cardiovascular disease; Diabetes mellitus; Periodontitis

Indexed keywords

ACARBOSE; ANGIOTENSIN RECEPTOR ANTAGONIST; CHOLESTEROL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIPEPTIDYL PEPTIDASE IV INHIBITOR; EXENDIN 4; GLIBENCLAMIDE; GLIMEPIRIDE; GLIPIZIDE; GLITAZONE DERIVATIVE; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; HEMOGLOBIN A1C; INSULIN; INSULIN ASPART; INSULIN DETEMIR; INSULIN GLARGINE; INSULIN GLULISINE; INSULIN LISPRO; ISOPHANE INSULIN; METFORMIN; MIGLITOL; NATEGLINIDE; PRAMLINTIDE; REPAGLINIDE; ROSIGLITAZONE; SITAGLIPTIN; SULFONYLUREA DERIVATIVE; THIAZIDE DIURETIC AGENT; UNINDEXED DRUG;

CANCER RISK; CANDIDIASIS; CARDIOVASCULAR RISK; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DIABETIC DIET; DIABETIC NEPHROPATHY; DIABETIC NEUROPATHY; DIABETIC RETINOPATHY; DISEASE EXACERBATION; DRUG DOSE TITRATION; EDEMA; GASTROINTESTINAL SYMPTOM; GINGIVITIS; GLYCEMIC CONTROL; HEADACHE; HUMAN; HYPOGLYCEMIA; INFLAMMATION; INSULIN DEFICIENCY; INTRAVENOUS GLUCOSE TOLERANCE TEST; LEUKOPLAKIA; LICHEN PLANUS; LIFESTYLE MODIFICATION; LOW DRUG DOSE; MONOTHERAPY; MOUTH CANCER; MOUTH DISEASE; MOUTH HYGIENE; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; ORAL GLUCOSE TOLERANCE TEST; PERIODONTITIS; PRECANCER; PRIMARY PREVENTION; PRIORITY JOURNAL; REVIEW; RHINOPHARYNGITIS; RISK ASSESSMENT; RISK FACTOR; SIDE EFFECT; URINARY TRACT INFECTION; VOMITING; WEIGHT GAIN; WEIGHT REDUCTION; XEROSTOMIA;

BLOOD GLUCOSE; CARDIOVASCULAR DISEASES; DIABETES COMPLICATIONS; DIABETES MELLITUS; HUMANS; MOUTH DISEASES;

EID: 39749129259     PISSN: 1354523X     EISSN: 16010825     Source Type: Journal    
DOI: 10.1111/j.1601-0825.2007.01425.x     Document Type: Review

References (60)

1. Adler AI, Stratton IM, Neil HA et al (2000). Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. BMJ 321 : 412 419.
2. Aljada A, Ghanim H, Mohanty P, Kapur N, Dandona P (2002). Insulin inhibits the pro-inflammatory transcription factor early growth response gene-1 (Egr)-1 expression in mononuclear cells (MNC) and reduces plasma tissue factor (TF) and plasminogen activator inhibitor-1 (PAI-1) concentrations. J Clin Endocrinol Metab 87 : 1419 1422.
3. Allen PF, McMillan AS (2003). A review of the functional and psychosocial outcomes of edentulousness treated with complete replacement dentures. J Can Dent Assoc 69 : 662 662e.
4. Amori RE, Lau J, Pittas AG (2007). Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis. JAMA 298 : 194 206.
5. Bagdade JD, Root RK, Bulger RJ (1974). Impaired leukocyte function in patients with poorly controlled diabetes. Diabetes 23 : 9 15.
6. Buchanan TA, Xiang AH, Peters RK et al (2002). Preservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk hispanic women. Diabetes 51 : 2796 2803.
7. Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M (2002). Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomized trial. Lancet 359 : 2072 2077.
8. Collins R, Armitage J, Parish S, Sleigh P, Peto R (2003). Heart Protection Collaborative Group. MRC-/-BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 361 : 2005 2016.
9. Coutinho M, Gerstein HC, Wang Y, Yusuf S (1999). The relationship between glucose and incident cardiovascular events. A metaregression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 years. Diabetes Care 22 : 233 240.
10. Dandona P, Aljada A, Mohanty P et al (2001). Insulin inhibits intranuclear nuclear factor kappaB and stimulates IkappaB in mononuclear cells in obese subjects: evidence for an anti-inflammatory effect? J Clin Endocrinol Metab 86 : 3257 3265.
11. Drucker DJ, Nauck MA (2006). The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 368 : 1696 1705.
12. Emslie-Smith AM, Boyle DIR, Evans JMM, Sullivan F, Morris AD (2001). Contraindications to metformin therapy in patients with Type 2 diabetes - a population-based study of adherence to prescribing guidelines. Diabet Med 18 : 483 488.
13. Fourlanos S, Perry C, Stein MS, Stankovich J, Harrison LC, Colman PG (2006). A clinical screening tool identifies autoimmune diabetes in adults. Diabetes Care 29 : 970 975.
14. Furnary AP, Zerr KJ, Grunkemeier GL, Starr A (1999). Continuous intravenous insulin infusion reduces the incidence of deep sternal wound infection in diabetic patients after cardiac surgical procedures. Ann Thorac Surg 67 : 352 360.
15. Gerich J, Raskin P, Jean-Louis L, Purkayastha D, Baron A (2005). PRESERVE: two year efficacy and safety of initial combination therapy with nateglinide or glyburide plus metformin. Diabetes Care 28 : 2093 2100.
16. Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. The DECODE Study Group on behalf of the European Diabetes Epidemiology Group (1999). Diabetes epidemiology: collaborative analysis of diagnostic criteria in Europe. Lancet 354 : 617 621.
17. Goutzanis L, Vairaktaris E, Yapijakis C et al (2007). Diabetes may increase risk for oral cancer through the insulin receptor substrate-1 and focal adhesion kinase pathway. Oral Oncol 43 : 165 173.
18. Grossi SG, Skrepcinski FB, DeCaro T et al (1997). Treatment of periodontal disease in diabetics reduces glycated hemoglobin. J Periodontol 68 : 713 719.
19. Hansson L, Zanchetti A, Carruthers SG et al (1998). Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet 351 : 1755 1762.
20. Home PD, Pocock SJ, Beck-Nielsen H et al (2007). Rosiglitazone evaluated for cardiovascular outcomes - an interim analysis. N Engl J Med 357 : 28 38.
21. Jones JA, Miller DR, Wehler CJ et al (2007). Does periodontal care improve glycemic control? The Department of Veterans Affairs Dental Diabetes Study. J Clin Periodontol 34 : 46 52.
22. Kahn SE, Haffner SM, Heise MA et al (2006). Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 355 : 2427 2443.
23. Knowler WC, Barrett-Connor E, Fowler SE et al (2002). Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 346 : 393 403.
24. LaRosa JC, Grundy SM, Waters DD et al (2005). Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 352 : 1425 1435.
25. Löe H (1993). Periodontal disease: the sixth complication of diabetes mellitus. Diabetes Care 16 : 329 334.
26. Loos BG, Craandijk J, Hoek FJ, Wertheim-van Dillen PM, van der Velden U (2000). Elevation of systemic markers related to cardiovascular diseases in the peripheral blood of periodontitis patients. J Periodontol 71 : 1528 1534.
27. Magnotti MA, Rayfield EJ (2007). An update on insulin injection devices. Insulin 2 : 173 181.
28. Narayan KM, Boyle JP, Thompson TJ, Sorensen SW, Williamson DF (2003). Lifetime risk for diabetes mellitus in the United States. JAMA 290 : 1884 1890.
29. Nathan DM, Cleary PA, Backlund JY et al (2005). Intensive diabetes treatment and cardiovascular disease in patients with type 1 Diabetes. The DCCT-/-EDIC Study Research Group. N Engl J Med 353 : 2643 2653.
30. Nissen SE, Wolski K (2007). Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 356 : 2457 2471.
31. Pan XR, Li GW, Hu YH et al (1997). Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance: the Da Qing IGT and Diabetes Study. Diabetes Care 20 : 537 544.
32. Perner A, Nielsen SE, Rask-Madsen J (2003). High glucose impairs superoxide production from isolated blood neutrophils. Intensive Care Med 29 : 642 645.
33. Petersen PE (2003). The World Oral Health Report 2003: continuous improvement of oral health in the 21st century - the approach of the WHO Global Oral Health Programme. Community Dent Oral Epidemiol 31 : 3 23.
34. Petrou-Amerikanou C, Markopoulos AK, Belazi M, Karamitsos D, Papanayotou P (1998). Prevalence of oral lichen planus in diabetes mellitus according to the type of diabetes. Oral Dis 4 : 37 40.
35. Promsudthi A, Pimapansri S, Deerochanawong C, Kanchanavasita W (2005). The effect of periodontal therapy on uncontrolled type 2 diabetes mellitus in older subjects. Oral Dis 11 : 293 298.
36. Resnick HE, Foster GL, Bardsley J, Ratner RE (2006). Achievement of American Diabetes Association clinical practice recommendations among U.S. adults with diabetes, 1999-2002: the National Health and Nutrition Examination Survey. Diabetes Care 29 : 531 537.
37. Rodrigues DC, Taba MJ, Novaes AB, Souza SL, Grisi MF (2003). Effect of non-surgical periodontal therapy on glycemic control in patients with type 2 diabetes mellitus. J Periodontol 74 : 1361 1367.
38. Roglic G, Unwin N, Bennett PH et al (2005). The burden of mortality attributable to diabetes: realistic estimates for the year 2000. Diabetes Care 28 : 2130 2135.
39. Rosenstock J, Hassman DR, Madder RD et al (2004). Repaglinide versus nateglinide monotherapy: a randomized, multicenter study. Diabetes Care 27 : 1265 1270.
40. Salpeter S, Greyber E, Pasternak G, Salpeter E (2006). Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. Cochrane Database Syst Rev 1 : CD002967.
41. Saremi A, Nelson RG, Tulloch-Reid M, Hanson RL, Sievers ML, Taylor GW, Shlossman M, Bennett PH, Genco R, Knowler WC (2005). Periodontal disease and mortality in type 2 diabetes. Diabetes Care 28 : 27 32.
42. Selvin E, Marinopoulos S, Berkenblit G et al (2004). Meta-analysis: glycosylated hemoglobin and cardiovascular disease in diabetes mellitus. Ann Intern Med 141 : 421 431.
43. Sheiham A, Steele JG, Marcenes W, Tsakos G, Finch S, Walls AW (2001a). Prevalence of impacts of dental and oral disorders and their effects on eating among older people; a national survey in Great Britain. Community Dent Oral Epidemiol 29 : 195 203.
44. Sheiham A, Steele JG, Marcenes W et al (2001b). The relationship among dental status, nutrient intake, and nutritional status in older people. J Dent Res 80 : 408 413.
45. Standards of Medical Care in Diabetes (2007). American Diabetes Association. Diabetes Care 30 : S4 S41.
46. Steinberg HO, Brechtel G, Johnson A, Fineberg N, Baron AD (1994). Insulin-mediated skeletal muscle vasodilation is nitric oxide dependent. A novel action of insulin to increase nitric oxide release. J Clin Invest 94 : 1172 1179.
47. Stewart JE, Wager KA, Friedlander AH, Zadeh HH (2001). The effect of periodontal treatment on glycemic control in patients with type 2 diabetes mellitus. J Clin Periodontol 28 : 306 310.
48. Tataranni PA, Bogardus C (2004). Metabolic abnormalities in the development of type 2 diabetes mellitus. In : LeRoith D, Olefsky JM, Taylor SI eds. Diabetes mellitus: a fundamental and clinical text. 3rd edn. Lippincott Williams & Wilkins : Philadelphia, pp. 797 807.
49. Taylor GW, Burt BA, Becker MP et al (1996). Severe periodontitis and risk for poor glycemic control in patients with non-insulin-dependent diabetes mellitus. J Periodontol 67 : 1085 1093.
50. The DCCT Research Group (1993). The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329 : 977 986.
51. The DREAM (Diabetes Reduction Assessment with ramipril and rosiglitazone medication) Investigators (2006). Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomized controlled trial. Lancet 368 : 1096 1105.
52. Trovati M, Anfossi G, Massucco P et al (1997). Insulin stimulates nitric oxide synthesis in human platelets and, through nitric oxide, increases platelet concentrations of both guanosine-30, 50-cyclic monophosphate and adenosine-30, 50-cyclic monophosphate. Diabetes 46 : 742 749.
53. Tsai C, Hayes C, Taylor GW (2002). Glycemic control of type 2 diabetes and severe periodontal disease in the US adult population. Community Dent Oral Epidemiol 30 : 182 192.
54. Tuomilehto J, Lindstrom J, Eriksson JG et al (2001). Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 344 : 1343 1350.
55. Ujpál M, Matos O, Bíbok G, Somogyi A, Szabó G, Suba Z (2004). Diabetes and oral tumors in Hungary. Epidemiological correlations. Diabetes Care 27 : 770 774.
56. UK Prospective Diabetes Study (UKPDS) Group (1998). Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352 : 837 853.
57. UK Prospective Diabetes Study (UKPDS) Group (1998). Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: (UKPDS 38). BMJ 317 : 703 713.
58. Van Den Berghe G, Wouters P, Weekers F et al (2001). Intensive insulin therapy in critically ill patients. N Engl J Med 345 : 1359 1367.
59. Worthley MI, Holmes AS, Willoughby SR et al (2007). The deleterious effects of hyperglycemia on platelet function in diabetic patients with acute coronary syndromes: mediation by superoxide production, resolution with intensive insulin administration. J Am Coll Cardiol 49 : 304 310.
60. Writing Team for the DCCT-/-EDIC Research group (2002). Effect of intensive therapy on the microvascular complications of type 1 diabetes mellitus. JAMA 287 : 2563 2569.